Meijuan Huang

9PUBLICATIONS
69CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapyMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 21, 2025
Drug allergy history predicts early progression-free survival benefit from PD-(L)1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study.

Wenhao Zhao, Min Yu, Youling Gong

|Aug 07, 2024
Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis.

Qiaofeng Zhong, Longfeng Zhang, Lin Wu

|Jan 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer.

Gen Lin, Zhijie Wang, Qian Chu

|Nov 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer.

Dingzhi Huang, Gen Lin, Qian Chu

|Aug 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.

Xiaojuan Zhou, Laiyan Zhou, Zhuoran Yao

|May 22, 2023
Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort.

Ruolan Xia, Yanying Li, Ling Yang

Pageof 2

Frequent Collaborators

3 joint publications

Dingzhi Huang

3 joint publications

Chengbo Han

3 joint publications

Fang Wu

2 joint publications

Gen Lin